Equillium, Inc.

Listed Company

EQCIK 0001746466NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-22.40M

Total Assets

$31.89M

Equity

$28.60M

Shares Out

63.23M

Op. Cash Flow

$-22.75M

Business

Equillium, Inc. is a clinical-stage biotechnology company that develops novel therapeutics to treat severe immuno-inflammatory disorders. It offers product candidates including itolizumab (EQ001), a first-in-class anti‑CD6 monoclonal antibody, and multi‑cytokine peptide inhibitors EQ101 and EQ302 derived from a proprietary discovery platform. The company operates clinical and preclinical development programs, a peptide discovery platform, and licensing and partnership activities. It targets the United States, Canada, Australia and New Zealand and relies on contract manufacturers and partners for supply and commercialization.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	—	41	36	16	—
Research and development	13	37	37	—	—
General and administrative	11	12	14	17	11
Total operating expenses	24	49	51	78	38
Loss from operations	−24	−8	−15	−62	−38
Interest income	833,000	1	2	420,000	57,000
Other income (expense), net	403,000	−818,000	−76,000	—	—
Total other income, net	1	563,000	2	—	—
Loss before income tax expense	−22	−8	−13	—	—
Income tax expense	0	400,000	600,000	0	—
Net loss	−22	−8	−13	−62	−39
Unrealized loss on available-for-sale securities, net	−3,000	−15,000	108,000	−38,000	−59,000
Foreign currency translation (loss) gain	−415,000	656,000	−44,000	252,000	218,000
Total other comprehensive (loss) income, net	−418,000	641,000	64,000	214,000	159,000
Comprehensive loss	−23	−7	−13	−62	−39
Net loss per share, basic	−0.39	−0.23	−0.38	−1.85	−1.36
Net loss per share, diluted	−0.39	−0.23	−0.38	−1.85	−1.36
Weighted-average number of common shares outstanding, basic	57	35	35	34	29
Weighted-average number of common shares outstanding, diluted	57	35	35	34	29

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	30	18	23	59	50
Short-term investments	—	4	18	12	30
Prepaid expenses and other current assets	761,000	2	5	3	3
Total current assets	31	25	49	77	83
Operating lease right-of-use assets	658,000	364,000	796,000	1	2
Property and equipment, net	164,000	262,000	315,000	391,000	237,000
Other assets	27,000	—	70,000	104,000	153,000
Total assets	32	26	51	78	85
Accounts payable	755,000	3	5	4	1
Accrued expenses	2	3	7	7	6
Current portion of operating lease liabilities	363,000	197,000	440,000	408,000	376,000
Total current liabilities	3	6	28	32	9
Long-term operating lease liabilities	356,000	187,000	384,000	824,000	1
Total liabilities	3	7	28	46	19
Commitments and contingencies	—	—	—	—	—
Common stock, $0.0001 par value; 200,000,000 shares authorized as of December 31, 2025 and 2024; 61,464,368 and 35,557,563 shares issued and outstanding as of December 31, 2025 and 2024, respectively	5,000	3,000	3,000	3,000	2,000
Additional paid-in capital	244	212	208	204	177
Accumulated other comprehensive income	363,000	781,000	140,000	76,000	−138,000
Accumulated deficit	−216	−194	−186	−172	−110
Total stockholders' equity	29	19	23	32	67
Total liabilities and stockholders' equity	32	26	51	78	85

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−22	−8	−13	−62	−39
Depreciation	100,000	100,000	100,000	118,000	—
Loss on disposal of property and equipment	19,000	—	—	—	—
Stock-based compensation	2	4	4	5	4
Net unrealized (gain) loss on foreign currency transactions	−474,000	794,000	58,000	260,000	240,000
Amortization of investments, net	−14,000	−754,000	−914,000	127,000	314,000
Deferred revenue	—	−16	−9	25	—
Accounts receivable	—	4	−897,000	−3	—
Prepaid expenses and other current assets	1	2	−2	−158,000	214,000
Accounts payable	−2	−2	723,000	3	−2
Accrued expenses	−2	−3	−554,000	432,000	3
Right-of-use assets and lease liabilities, net	42,000	−9,000	−13,000	75,000	−37,000
Net cash used in operating activities	−23	−19	−22	−9	−32
Purchases of property and equipment	−48,000	−85,000	−50,000	−279,000	−57,000
Proceeds from disposal of property and equipment	12,000	—	—	—	—
Purchases of short-term investments	—	−18	−55	−15	−33
Maturities of short-term investments	5	32	50	33	60
Net cash provided by investing activities	4	14	−5	19	27
Proceeds from a private placement of common stock and pre-funded warrants, net of issuance costs	28	—	—	—	—
Proceeds from exercise of stock options	2	4,000	—	0	900,000
Net cash provided by financing activities	30	164,000	−9	−1	31
Effect of exchange rate changes on cash and cash equivalents	47,000	−83,000	−118,000	5,000	−2,000
Net increase (decrease) in cash and cash equivalents	12	−5	−36	9	26
Right-of-use assets obtained in exchange for lease obligations	548,000	—	—	0	2
ATM facility issuance costs reclassed from other current assets	392,000	—	—	—	—
Exercise Of Stock Options Issuance Costs In Accounts Payable	5,000	—	—	—	—
Cash paid for income taxes, net of refunds	352,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro